The Experts below are selected from a list of 3903 Experts worldwide ranked by ideXlab platform
Mark A. Richards - One of the best experts on this subject based on the ideXlab platform.
-
brain natriuretic peptide and n terminal brain natriuretic peptide in the diagnosis of heart failure in patients with acute shortness of breath
Journal of the American College of Cardiology, 2003Co-Authors: John G. Lainchbury, Elizabeth J Campbell, Gary M Nicholls, Chris Frampton, Timothy G. Yandle, Mark A. RichardsAbstract:Abstract Objectives This study sought to compare the utility of measurement of plasma brain natriuretic peptide (BNP) and N-terminal brain natriuretic peptide (N-BNP) in the diagnosis of heart failure (HF) in patients with acute dyspnea. Background Plasma BNP is useful in differentiating HF from other causes of dyspnea in the emergency department. The N-terminal component of BNP has a longer half-life, and in HF increases in plasma N-BNP are proportionately greater. Methods We studied 205 patients (average age 70 ± 14 years) presenting to the emergency department with acute dyspnea. Brain natriuretic peptide was analyzed using a point-of-care test and two locally developed Radioimmunoassays. N-terminal BNP was measured using a locally developed radioimmunoassay and a commercially available assay. Final diagnosis of HF was adjudicated by two cardiologists. Results Patients with HF (n = 70) had higher mean levels of both hormones by all assays (p Conclusions Measurement of BNP or N-BNP is useful in the diagnosis of HF in acute dyspnea. Commercially available assays compare favorably with well-validated laboratory assays. Differences in sensitivity and specificity may influence the assay choice in this setting.
John G. Lainchbury - One of the best experts on this subject based on the ideXlab platform.
-
brain natriuretic peptide and n terminal brain natriuretic peptide in the diagnosis of heart failure in patients with acute shortness of breath
Journal of the American College of Cardiology, 2003Co-Authors: John G. Lainchbury, Elizabeth J Campbell, Gary M Nicholls, Chris Frampton, Timothy G. Yandle, Mark A. RichardsAbstract:Abstract Objectives This study sought to compare the utility of measurement of plasma brain natriuretic peptide (BNP) and N-terminal brain natriuretic peptide (N-BNP) in the diagnosis of heart failure (HF) in patients with acute dyspnea. Background Plasma BNP is useful in differentiating HF from other causes of dyspnea in the emergency department. The N-terminal component of BNP has a longer half-life, and in HF increases in plasma N-BNP are proportionately greater. Methods We studied 205 patients (average age 70 ± 14 years) presenting to the emergency department with acute dyspnea. Brain natriuretic peptide was analyzed using a point-of-care test and two locally developed Radioimmunoassays. N-terminal BNP was measured using a locally developed radioimmunoassay and a commercially available assay. Final diagnosis of HF was adjudicated by two cardiologists. Results Patients with HF (n = 70) had higher mean levels of both hormones by all assays (p Conclusions Measurement of BNP or N-BNP is useful in the diagnosis of HF in acute dyspnea. Commercially available assays compare favorably with well-validated laboratory assays. Differences in sensitivity and specificity may influence the assay choice in this setting.
Yin Xin-hua - One of the best experts on this subject based on the ideXlab platform.
-
Positive association between musclin and insulin resistance in obesity: evidence of a human study and an animal experiment
NUTRITION & METABOLISM, 2017Co-Authors: Chen Wen-jia, Liu Yue, Sui Yu-bin, Yang Hong-tao, Chang Jin-rui, Tang Chao-shu, Qi Yong-fen, Zhang Jing, Yin Xin-huaAbstract:Background: Musclin is a novel skeletal muscle-derived secretory factor considered to be a potent regulator of the glucose metabolism and therefore may contribute to the pathogenesis of obesity and insulin resistance (IR). Methods: To test this hypothesis, we examined the plasma musclin levels in overweight/obese subjects and lean controls. Rats on a high fat diet (HFD) were used as the annimal model of obesity. Radioimmunoassay and western blot were used to determine musclin levels in plasma and skeletal muscle. Results: According to Radioimmunoassays, the overweight/obese subjects exhibited elevated musclin plasma levels compared with the lean controls (89.49 +/- 19.00 ng/L vs 80.39 +/- 16.35 ng/L, P < 0.01). The musclin levels were positively correlated with triglyceride, fasting plasma glucose, and homeostasis model assessment of IR levels. These observations were confirmed with a high-fat diet(HFD) rat model. HFD rats also exhibited increased musclin immunoreactivity in plasma (P < 0.01) and in skeletal muscle (P < 0.05), as well as increased musclin mRNA levels in skeletal muscle (P < 0.01). Musclin incubation significantly inhibited muscles H-3-2-DG uptake in the normal diet(ND) group (P < 0.01). The protein expression of glucose transporter type 4 was significantly down regulated by 30% (P < 0.05) in the ND group after soleusmuscle was incubated with musclin compared with the control. Musclin incubation also increased the protein levels of glucose-regulated protein (GRP) 78 and GRP94 by 146.8 and 54% (both P < 0.05), respectively, in ND rats. Conclusions: Our data support the hypothesis that musclin has a strong relationship with obesity-associated IR by impairing the glucose metabolism and, at least in part, through causing endoplasmic reticulum stress.Harbin Medical University [2016LCZX41]; First Affiliated Hospital of Harbin Medical University Science Fund [2014B08]; Hei-longjiang Postdoctoral Grant [LBH Z14116]SCI(E)ARTICLE1
Susan F Greenhut - One of the best experts on this subject based on the ideXlab platform.
-
measurement of steroid sex hormones in serum a comparison of radioimmunoassay and mass spectrometry
Steroids, 2002Co-Authors: Joanne F Dorgan, Thomas R Fears, Robert P Mcmahon, Lisa Aronson Friedman, Blossom H Patterson, Susan F GreenhutAbstract:Concern has been raised about the adequacy of Radioimmunoassays to measure steroid sex hormones in population studies. We compared steroid sex hormone measurements in serum by radioimmunoassay with mass spectrometry. Four male and four female serum pools with known relative concentrations of steroid sex hormones were measured multiple times by both methods. Because measurements are expected to increase linearly with concentration for each sex, we examined whether the linear regressions of hormone measurements on concentration were the same for radioimmunoassay and mass spectrometry. Estradiol, estrone, androstenedione, testosterone, and dehydroepiandrosterone sulfate were measured in female pools; testosterone, dihydrotestosterone, androstenedione, and dehydroepiandrosterone sulfate were measured in male pools. Regression slopes for radioimmunoassay and mass spectrometry measurements were comparable for all hormones except androstenedione, which had a steeper slope when measured by mass spectrometry (P ≤ 0.02). Intercepts for radioimmunoassay and mass spectrometry were similar and close to zero for estradiol, androstenedione, dehydroepiandrosterone sulfate, and in male samples, testosterone. For testosterone in female samples, estrone, and dihydrotestosterone, radioimmunoassay and mass spectrometry intercepts differed significantly. Standard deviations of individual measurements by radioimmunoassay and mass spectrometry differed by hormone and serum concentration; neither method consistently measured hormone concentrations with less variability. Our findings suggest that although absolute concentrations may differ for some hormones, radioimmunoassay and mass spectrometry can yield similar estimates of between subject differences in serum concentrations of most steroid sex hormones commonly measured in population studies. Relative power of studies using radioimmunoassay and mass spectrometry will depend on the hormones measured and their serum concentrations.
Elizabeth J Campbell - One of the best experts on this subject based on the ideXlab platform.
-
brain natriuretic peptide and n terminal brain natriuretic peptide in the diagnosis of heart failure in patients with acute shortness of breath
Journal of the American College of Cardiology, 2003Co-Authors: John G. Lainchbury, Elizabeth J Campbell, Gary M Nicholls, Chris Frampton, Timothy G. Yandle, Mark A. RichardsAbstract:Abstract Objectives This study sought to compare the utility of measurement of plasma brain natriuretic peptide (BNP) and N-terminal brain natriuretic peptide (N-BNP) in the diagnosis of heart failure (HF) in patients with acute dyspnea. Background Plasma BNP is useful in differentiating HF from other causes of dyspnea in the emergency department. The N-terminal component of BNP has a longer half-life, and in HF increases in plasma N-BNP are proportionately greater. Methods We studied 205 patients (average age 70 ± 14 years) presenting to the emergency department with acute dyspnea. Brain natriuretic peptide was analyzed using a point-of-care test and two locally developed Radioimmunoassays. N-terminal BNP was measured using a locally developed radioimmunoassay and a commercially available assay. Final diagnosis of HF was adjudicated by two cardiologists. Results Patients with HF (n = 70) had higher mean levels of both hormones by all assays (p Conclusions Measurement of BNP or N-BNP is useful in the diagnosis of HF in acute dyspnea. Commercially available assays compare favorably with well-validated laboratory assays. Differences in sensitivity and specificity may influence the assay choice in this setting.
